Eli Lilly has announced the acquisition of a manufacturing facility in Wisconsin from Nexus Pharmaceuticals for an undisclosed price. The facility will be used to produce injectable medicines, including addressing shortages of Mounjaro and Zepbound. This acquisition is part of Eli Lilly's efforts to expand its fill-finish capacity for GLP-1s, a class of drugs used in the treatment of diabetes and obesity.
Lilly to buy injectable drug plant in manufacturing ramp-up https://t.co/HYGhDsCIMi $LLY by @Lilah_Alvarado
Pharmalot.. Pharmalittle.. Good Morning: We’re reading about Lilly buying a plant, a Pfizer antibiotic, and more news.. https://t.co/4vgTlKTfrw #pharma #Zantac #patents #Medicare #antibiotics #weightloss #obesity $GSK $SNY $PFE $BMY $MRK $TAK $LLY $VNDA
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound. https://t.co/Jutr6q2ONl
Eli Lilly's efforts to build fill-finish capacity for GLP-1s continues. Lilly has just announced a deal to buy a fill-finish facility off sterile manufacturer Nexus Pharmaceuticals for an undisclosed price. https://t.co/lCBjrc9HPZ https://t.co/w6009G4IDS
Eli Lilly to acquire manufacturing facility from Nexus Pharma https://t.co/PNSrlhzCLw https://t.co/dJj6WA2Cng
Eli Lilly said on Monday that it will acquire a manufacturing facility from Nexus Pharmaceuticals to produce injectable medicines. https://t.co/BJN9DT3FZ2 https://t.co/BJN9DT3FZ2